Cencora Projects 8% to 10% Earnings Growth
The drug distributor reported record fiscal 2026 revenue and forecast adjusted earnings growth for fiscal 2027 as it expands into specialty oncology care.
Updated on Nov. 17, 2026 in Healthcare

Cencora, Inc. reported $337.4 billion in annual revenue for fiscal 2026 and adjusted diluted earnings per share of $17.97, up from $16. The company projects adjusted earnings growth of 8% to 10% for fiscal 2027, with adjusted diluted EPS of $19.40 to $19.75.
Why it matters
The results reflect Cencora's push into specialty healthcare services, led by its February 2026 acquisition of OneOncology, which lifted gross margin and increased borrowing costs. Its pending deal for American Oncology Network would further extend its ties to specialty physician practices.
Fourth-quarter gross profit rose 21.9% to $3.6 billion, and gross margin increased 55 basis points to 4.08%, mainly from the OneOncology contribution. Fourth-quarter net interest expense climbed $58.5 million to $136.3 million, which the company tied to debt issued to finance that deal.
The players
Cencora, Inc.
Cencora is a large pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, that supplies medicines to pharmacies, hospitals and healthcare providers.
The details
Cencora will replace its geographic reporting structure with business-focused segments starting in the first quarter of fiscal 2027. The company also raised its quarterly dividend 10% to 66 cents per common share from 60 cents, and signed a definitive agreement to acquire American Oncology Network, which has about 350 oncology providers across 21 states.
Timeline
February 2026: Cencora acquired OneOncology.
September 30, 2026: Fourth-quarter reporting period ended.
November 3, 2026: Quarterly dividend declared.
November 13, 2026: Dividend record date for shareholders.
November 30, 2026: Dividend payable to shareholders.
Market Landscape
Cencora's OneOncology acquisition in February 2026 set the stage for its push into specialty oncology care, which the company treats as central to its growth strategy. The pending American Oncology Network deal would deepen that position by adding relationships with specialty physician practices.
Shareholders will receive the higher 66-cent quarterly dividend, a 10% increase, with payment scheduled for November 30, 2026. Patients and providers in the specialty oncology space may see the effects of Cencora's expanding network of oncology practices as its acquisitions take shape.
The takeaway
Growth in specialty care services is becoming a larger share of Cencora's strategy, and its revenue and margin gains from acquisitions like OneOncology show how that shift can lift results even as borrowing costs rise.
What happens next
Cencora expects the Profarma sale to close during the first quarter of fiscal 2027, and the dividend record and payable dates fall in November 2026.
Further reading
Track more company earnings and industry moves in the Healthcare section.






